Publications by authors named "L Checkley"
Article Synopsis
- This study investigates the rates of buprenorphine precipitated opioid withdrawal (BPOW) among patients using fentanyl who received treatment in an emergency department (ED).
- Over 28 months, only 2.6% of the 113 fentanyl users treated with buprenorphine experienced BPOW, suggesting a low prevalence in this group.
- However, when BPOW does occur, it can be severe, with some patients needing intensive care and extended hospital stays.
Background: Artemisinin partial resistance (ART-R) has spread throughout Southeast Asia and mutations in , the molecular marker of resistance, are widely reported in East Africa. Effective assays and robust phenotypes are crucial for monitoring populations for the emergence and spread of resistance. The recently developed extended Recovery Ring-stage Survival Assay used a qPCR-based readout to reduce the labor intensiveness for phenotyping of ART-R and improved correlation with the clinical phenotype of ART-R.
View Article and Find Full Text PDFArticle Synopsis
- Artemisinin partial resistance (ART-R) has been detected in eastern Africa, prompting the need for ongoing monitoring of artemisinin susceptibility in malaria parasites.
- Traditional methods like the ring-stage survival assay (RSA) rely on microscopy, which is slow and subjective, while the new extended recovery ring-stage survival assay (eRRSA) uses qPCR for better efficiency and has proven effective on cultured clones.
- A study comparing both methods on 122 fresh isolates from Uganda showed strong correlations between results, with eRRSA offering a more scalable and effective approach to identifying resistance in malaria strains.
Piperaquine (PPQ) is widely used in combination with dihydroartemisinin as a first-line treatment against malaria. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the () and increased copies of (). We generated a cross between a Cambodia-derived multidrug-resistant KEL1/PLA1 lineage isolate (KH004) and a drug-susceptible Malawian parasite (Mal31).
View Article and Find Full Text PDFPiperaquine (PPQ) is widely used in combination with dihydroartemisinin (DHA) as a first-line treatment against malaria parasites. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the () and increased copies of (). We generated a cross between a Cambodia-derived multi-drug resistant KEL1/PLA1 lineage isolate (KH004) and a drug susceptible parasite isolated in Malawi (Mal31).
View Article and Find Full Text PDF